After-Hours Stock Movers 08/23: (CARA) (PANW) (BXC) Higher; (TBPH) (MARK) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Palo Alto Networks (PANW) PT Raised to $500 at Piper Sandler
August 24, 2021 8:48 AM EDTPiper Sandler analyst Rob Owens raised the price target on Palo Alto Networks (NYSE: PANW) to $500.00 (from $450.00) while maintaining an Overweight rating following results.
The analyst commented, "Highlights include billings and revenue acceleration, the first quarter ever of $2B+ bookings, and impressive... More
Palo Alto Networks (PANW) PT Raised to $509 at BTIG
August 24, 2021 7:21 AM EDTBTIG analyst Gray Powerll raised the price target on Palo Alto Networks (NYSE: PANW) to $509.00 (from $460.00) while maintaining a Buy rating.
... MorePalo Alto Networks (PANW) PT Raised to $475 at Cowen
August 24, 2021 6:51 AM EDTCowen analyst Shaul Eyal raised the price target on Palo Alto Networks (NYSE: PANW) to $475.00 (from $425.00) while maintaining an Outperform rating.
The analyst commented, "PANW's better than expected results and improved guidance should alleviate recent investors' concerns about potential margin erosion, mgnt shuffle, and... More
Theravance Biopharma (TBPH) PT Lowered to $18 at Needham & Company
August 24, 2021 6:24 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $18.00 (from $32.00) while maintaining a Buy rating.
The analyst commented, "TBPH announced yesterday the izencitinib Ph2b RHEA trial in Ulcerative Colitis (UC) failed to demonstrate efficacy vs... More
